RxDoctor Payments Data

Anas Alzuhaili, MD

Emergency Medicine · Jeffersonville, INNPI 1417188491

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 49.0% of the total. Reporting peaked in 2021 at $485 and has fallen 84.6% since, to $75 in 2024. Among emergency medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$935in general payments, 2019–2025

Across 58 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$459
  • Amgen$74
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$74
  • Indivior Inc.$72
  • Currax Pharmaceuticals LLC$54
  • Kowa Pharmaceuticals America, Inc.$37
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$90096%
  • Education$354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$935 in reported general payments places this provider in the 95th percentile of 1,073 emergency medicine providers in Indiana.

See all emergency medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$82,534
Medicare patients
466
Services billed
1,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl44$1,571
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav96$1,160
Ondansetron OdtOndansetron39$662
Ciprofloxacin Hcl99$625
Gabapentin49$613
Ketorolac Tromethamine46$541
Albuterol Sulfate HfaAlbuterol Sulfate26$518
Metronidazole50$354
Prednisone162$326
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$257
Doxycycline Hyclate29$249
Cephalexin32$218
Omeprazole39$210
Cyclobenzaprine Hcl54$200
Ondansetron Hcl27$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone$35$1,57144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,073 emergency medicine providers in Indiana.

Other emergency medicine in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →